biostudies-literatureUnknown8(6)Young KRamucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.Therapeutic advances in gastroenterology373-83https://www.ebi.ac.uk/biostudies/studies/S-EPMC4622287biostudies-literatureRamucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma.PMC4622287Young KSmyth EChau IfalseRamucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma.Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.2015-01-01T00:00:00Z2015 Nov2024-11-21T09:26:52.72Z2019-03-27T02:00:51ZS-EPMC46222872655789310.1177/1756283x1559258610.1177/1756283X15592586